ADA 2026 featured incretin therapy advances, survodutide phase 3 data in metabolic liver disease, and cardiovascular risk reduction with evolocumab.
Anne Komé, PharmD
Advertisement
Anne Komé, PharmD, CPP, BCACP, CDCES, is a clinical pharmacist practitioner in the Endocrinology Clinic at the UNC Chapel Hill Medical Center.
Articles by Anne Komé, PharmD
Anne Komé, PharmD, explains that diabetes drug development is shifting to concurrent testing of metabolic effects.
ADA 2026 research showed how oral ketones, irisin, and SGLT2 inhibitors may reveal new metabolic pathways beyond glucose control.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes
2
National HIV Testing Day Highlights Expanding PrEP, PEP Access, Persistent Barriers
3
Treatment Burden, End-of-Life Symptom Gaps in Multiple Myeloma
4
Health Equity & Access Weekly Roundup: June 26, 2026
5